Ask about this productRelated genes to: RBM10 antibody
- Gene:
- RBM10 NIH gene
- Name:
- RNA binding motif protein 10
- Previous symbol:
- -
- Synonyms:
- DXS8237E, KIAA0122, GPATC9, ZRANB5, GPATCH9, S1-1
- Chromosome:
- Xp11.3
- Locus Type:
- gene with protein product
- Date approved:
- 2000-02-21
- Date modifiied:
- 2018-10-16
Related products to: RBM10 antibody
Related articles to: RBM10 antibody
- Early-stage EGFR-mutant lung adenocarcinoma (LUAD) demonstrates heterogeneous outcomes after curative surgery, yet adjuvant treatment decisions are guided by pathological stage alone. Following the ADAURA trial, adjuvant osimertinib is the standard of care for resected stage IB-IIIA EGFR-mutant LUAD; however, real-world data demonstrate that up to 40% of patients remain disease-free at five years without adjuvant osimertinib, underscoring the need for improved risk stratification. - Source: PubMed
Publication date: 2026/09/16
Saw Stephanie P LPang MengyuanYeo Jia ChiAlvarez Jacob J SSim Ngak LengGuo Amanda YKadioglu SinemLau Eunice L YLau Yi TingOdinokov DenisGetty VictorLai Gillianne G YLim Darren W TKanesvaran RavindranAng Mei-KimNg Quan SingTan Wan LingTan Wei ChongTan Aaron CWong Sophia Y NSeet Amanda O LHoo ReginaOng Boon-HeanLim Tony K HSkanderup Anders JacobsenTan Daniel S W - Epidermal growth factor receptor (EGFR) exon 19 deletion subtypes may be associated with differential survival outcomes following EGFR-tyrosine kinase inhibitor treatment. However, evidence remains scarce, particularly regarding osimertinib, and the underlying biological mechanisms are poorly understood. We aimed to compare survival outcomes among EGFR exon 19 deletion subtypes in patients with non-small cell lung cancer (NSCLC) treated with osimertinib. - Source: PubMed
Publication date: 2026/08/31
Hatano HirotoYoshida TatsuyaHigashiyama Ryoko InabaShirasawa MasayukiNakahara YoshiroNaoki KatsuhikoNokihara HiroshiGosho KentaroUehara YujiHosomi YukioKiritani AyuWakui HiroshiShinno YukiOkuma YusukeHorinouchi HidehitoYamamoto NoboruGoto Yasushi - Bladder cancer brain metastasis (BrM) remains a poorly characterized clinical entity in neuro-oncology. The current study combines clinicopathologic and genomic sequencing data to identify prognostic factors in bladder cancer BrM. - Source: PubMed
Publication date: 2026/08/18
Manoranjan BranavanZeller SabrinaPrice HannahReiner Anne SRosenberg Jonathan EIyer GopaMoss Nelson S - Most thyroid cancers are initiated by alterations activating the mitogen-activated protein kinase (MAPK) pathway and progress via additional genomic events. Because papillary thyroid carcinoma (PTC) generally has a favorable prognosis and rarely advances, knowledge about later-acquired genomic alterations and their impact on prognosis is limited. - Source: PubMed
Publication date: 2026/07/10
Toda SojiHiroshima YukihikoIwasaki HiroyukiKadoya MeiSuzuki ChihiroYamazaki HaruhikoOkubo YoichiroSaito AyaMasudo Katsuhiko - SMARCA4-deficient thoracic undifferentiated tumor is a rare and highly aggressive subtype of lung cancer defined in the 2021 World Health Organization classification. Its scarcity and highly undifferentiated histology limit the availability of representative in vitro models and hinder therapeutic development. In this study, we established a novel cell line, TRI-LC21, from the primary tumor of a patient with lung cancer showing pathological features consistent with this entity. TRI-LC21 exhibited stable proliferation, strong colony-forming ability, and robust tumorigenicity in subcutaneous xenograft models. Xenograft tumors recapitulated the histological features and immunophenotype of the original tumor. Cell line authenticity was confirmed by short tandem repeat profiling, and mycoplasma contamination was excluded. Whole-exome sequencing revealed SMARCA4 loss accompanied by co-mutations in TP53, STK11, RBM10, and ARHGAP35. Transcriptome analysis demonstrated decreased expression of epithelial-associated genes and increased expression of stemness- and plasticity-related programs, consistent with an undifferentiated phenotype. Collectively, TRI-LC21 faithfully recapitulates the histological, immunophenotypic, and molecular characteristics of this tumor type and provides a valuable in vitro model for mechanistic investigation and preclinical studies. - Source: PubMed
Publication date: 2026/07/09
Li ShashaLuo HaoWu DongshengKu YinLuo NanzhiGong ZhipengZhou WenjingXie XinyiZhou GuanyuChen YaohuiLiu Lunxu